" Weston, Florida, January 14, 2006 Cytorex Biosciences, Inc. (Cytorex), a Florida based biotechnology company, announced today the publication in the January 2006 issue of the Journal of Carcinogenesis, of a research report related to in-vitro efficacy testing in cancer cell lines and normal cell lines, with Cytoreg®, their lead anti-cancer compound. The title of the publication is: "Cytoreg® inhibits growth and proliferation of human adenocarcinoma cells via induction of apoptosis". The corresponding author is James Kumi-Diaka, DVM, PhD, from Florida Atlantic University (FAU), and the co-authors of the report are: Manzur Hassanhi, MD, PhD , professor of Immunology and Cancer Research Scientist, from the University of Zulia (Venezuela), Brown Jayaan(FAU), Kendra Merchant (FAU) , Carlos M Garcia (Cytorex), and William Jimenez (Cytorex). Abstract: "Cancer is one of the devastating neovascular diseases that incapacitate so many people the world over. Recent reports from the National Cancer Institute indicate some significant gain therapy and cancer management as seen in the increase in the 5-year survival rate over the past two decades. Although near-perfect cure rate have been reported in the early-stage disease, these data reveal high recurrence rate and serious side effects including second malignancies and fatalities. Most of the currently used anticancer agents are only effective against proliferating cancer cells. Thus attention has been focused on potential anti-cancer agents capable of killing cancer cells independent of the cell cycle state, to ensure effective elimination of most cancer cells. The objective of this study was to test the Chemosensitivity and potential mechanism of action of a novel cancer drug, Cytoreg®, in a panel of human cancer cells. Methods: the study was performed using a series of bioassays including Trypan blue exclusion, MTS Growth inhibition, LDH-cytotoxicity, TUNEL-Terminal DNA fragmentation Apoptosis Assay, and the Caspase protease CPP32 activity assays. Results: Cytoreg® induced significant dose- and time-dependent inhibition of growth in all the cells; with significant differences in chemosensitivity (P 1:300). Cytoreg®-induced caspase protease-3 (CPP32) activation significantly and positively correlated with apoptosis induction and growth inhibition; thus implicating CPP32 as the principal death pathway in Cytoreg®-induced apoptosis. Conclusion: Cytoreg® exerted a dose-and time-dependent growth inhibitory effect in all the target cells through induction of apoptosis via the CPP32 death pathway, independent of hormonal sensitivity of the cells. The present data indicate that not only could CPP32 provide a potential target for regulation of Cytoreg®-induced apoptosis but also that Cytoreg® could play a significant role in chemotherapeutic regimen in many human malignant tumors." "This is the first of several research reports about Cytoreg® we plan to submit, during 2006. to peer-reviewed journals", said Dr. James Kumi-Diaka, Professor of Biology of Cancer at Florida Atlantic University in Davie, Florida. "Cytoreg® has great potential as an anti-cancer compound, and additional research has shown that this compound's toxicity level is very low if compared with current approved chemotherapeutical agents", indicated Dr. Manzur Hassanhi, Professor of Immunology and Cancer Research Scientist of the University of Zulia (Maracaibo-Venezuela). Both Kumi-Diaka and Hasannhi, have lead since 2003 a multinational research team involved in the discovery of Cytoreg® as an anti-cancer agent. According to Cytorex's Vice-President & CFO, William Jimenez, who is also a co-author of this research report, "Cytoreg® is a therapeutic agent for cellular regulation, with antineoplastic properties which may also be used to fight immunological diseases. Cytoreg® constitutes a balanced mixture of strong and weak acids in an aqueous medium; resembling a buffer without using salts. Cytoreg® is transferred into a cellular system through ionic transport due to its low molecular weight, where each ion acts concurrently in cells, turning Cytoreg® into a highly efficient "smart-drug." Cytoreg®'s numerous mechanisms of action are exerted through the cellular membrane". A complete PDF version of the report is can be accessed through the Journal of Carcinogenesis web page: http://www.carcinogenesis.com/content/pdf/1477-3163-5-1.pdf For more information, please contact: 1-954-937-8519 USA), or send an email message to: [email protected] .